Revenues |
3 Months Ended |
|---|---|
Mar. 31, 2025 | |
| Revenues | |
| Revenues | 3 Revenues The Company recorded no revenue for the three months ended March 31, 2025 and 2024, respectively. We recorded license revenue as a result of having reached milestones pursuant to our License and Collaboration Agreement, dated May 15, 2021, with Corxel Pharmaceuticals, or “Corxel,” formerly known as Ji Xing Pharmaceuticals Limited (such party “Ji Xing,” and such agreement, the “Ji Xing License Agreement”). During the three months ended March 31, 2025 and 2024, no milestones were achieved under this agreement. For details on the arrangement with Corxel, see Note 3 to our audited consolidated financial statements for the year ended December 31, 2024, filed on Form 10-K. |